Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector


All Data

Filters Filter refresh
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PNT2002

            Therapeutic Area: Oncology Product Name: PNT2002

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $20.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing August 04, 2020


            Financing will be used to strengthen POINT’s position as a leader in radioligand development which includes PNT2002, a 177Lu-PSMA radiotherapeutic to treat prostate cancer and commercialization through investment in their pipeline as well as manufacturing capabilities.